Palvella Therapeutics Secures Patent for QTORIN™ Rapamycin, Strengthening Intellectual Property Strategy Through 2038
18/6 13:42
Palvella Therapeutics received a patent for QTORIN™ rapamycin, enhancing its exclusivity strategy in treating rare skin diseases....